PMID- 23532748
OWN - NLM
STAT- MEDLINE
DCOM- 20131227
LR  - 20220321
IS  - 1099-1077 (Electronic)
IS  - 0885-6222 (Linking)
VI  - 28
IP  - 2
DP  - 2013 Mar
TI  - Levels of TNF-alpha, soluble TNF receptors (sTNFR1, sTNFR2), and cognition in bipolar 
      disorder.
PG  - 160-7
LID - 10.1002/hup.2301 [doi]
AB  - OBJECTIVE: Tumor necrosis factor-alpha (TNF-alpha) may play an important role in 
      bipolar disorder (BD) pathogenesis. There is only one study about a relationship 
      between TNF-alpha levels and cognitive impairments in BD. The aim of the present 
      study was to see whether TNF-alpha, soluble P55 TNF receptor (sTNFR1), and soluble 
      P75 TNF receptor (sTNFR2) levels in BD patients are different from controls and 
      to investigate the relationships between the levels of TNF-alpha, sTNFR1, and sTNFR2 
      and the cognitive functions in euthymic BD patients and controls. METHODS: We 
      assessed 54 BD type I patients and 18 controls by using a battery of 
      neuropsychological tests. Serum TNF-alpha levels were measured using a commercially 
      available enzyme-linked immunosorbent assay, whereas serum sTNFR1 and sTNFR2 
      levels were measured using a commercially enzyme-amplified sensitivity 
      immunoassay kit. RESULTS: We found that levels of sTNFR1 and sTNFR2 in BD 
      patients were different from controls. No difference was detected between the BD 
      group and the control group for levels of TNF-alpha. TNF-alpha level was found to have a 
      negative correlation with the delayed recall in RAVLT. CONCLUSIONS: High levels 
      of sTNFR1 and sTNFR2 in euthymic patients showed that it may support that 
      proinflammatory process continues in euthymic period. This is the first study 
      which showed increased sTNFR2 levels in euthymic period, which could be 
      interpreted as a compensatory mechanism and again the first which deals with 
      verbal memory.
CI  - Copyright (c) 2013 John Wiley & Sons, Ltd.
FAU - Doganavsargil-Baysal, Ozge
AU  - Doganavsargil-Baysal O
AD  - Department of Psychiatry, Akdeniz University Medical Faculty, Antalya, 07070, 
      Turkey. oavsargil@akdeniz.edu.tr
FAU - Cinemre, Buket
AU  - Cinemre B
FAU - Aksoy, Umut Mert
AU  - Aksoy UM
FAU - Akbas, Halide
AU  - Akbas H
FAU - Metin, Ozmen
AU  - Metin O
FAU - Fettahoglu, Cigil
AU  - Fettahoglu C
FAU - Gokmen, Zehra
AU  - Gokmen Z
FAU - Davran, Fatih
AU  - Davran F
LA  - eng
PT  - Journal Article
PL  - England
TA  - Hum Psychopharmacol
JT  - Human psychopharmacology
JID - 8702539
RN  - 0 (Biomarkers)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type I)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type II)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Bipolar Disorder/*blood/epidemiology/psychology
MH  - Case-Control Studies
MH  - Cognition/physiology
MH  - Cognition Disorders/*blood/epidemiology/psychology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neuropsychological Tests
MH  - Receptors, Tumor Necrosis Factor, Type I/biosynthesis/*blood
MH  - Receptors, Tumor Necrosis Factor, Type II/biosynthesis/*blood
MH  - Solubility
MH  - Tumor Necrosis Factor-alpha/biosynthesis/*blood
MH  - Up-Regulation/physiology
EDAT- 2013/03/28 06:00
MHDA- 2013/12/29 06:00
CRDT- 2013/03/28 06:00
PHST- 2012/07/30 00:00 [received]
PHST- 2012/12/17 00:00 [revised]
PHST- 2013/01/29 00:00 [accepted]
PHST- 2013/03/28 06:00 [entrez]
PHST- 2013/03/28 06:00 [pubmed]
PHST- 2013/12/29 06:00 [medline]
AID - 10.1002/hup.2301 [doi]
PST - ppublish
SO  - Hum Psychopharmacol. 2013 Mar;28(2):160-7. doi: 10.1002/hup.2301.